BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $68.4 million versus the consensus estimate of $71.47 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.